论文部分内容阅读
目的观察贝伐单抗联合顺铂腔内灌注治疗恶性胸腹水的临床效果。方法选择2013年3月—2014年9月收治的60例恶性胸腹水患者作为研究对象,随机分为对照组和观察组各30例。对照组给予顺铂腔内灌注方案,观察组接受贝伐单抗联合顺铂腔内灌注方案。比较两组患者的治疗效果、不良反应发生情况及生活质量评分。计量资料采用t检验,计数资料采用χ2检验,P<0.05为差异有统计学意义。结果观察组整体缓解率为80.0%,对照组为40.0%,两组比较差异有统计学意义(P<0.05)。观察组治疗后生活质量评分为(46.8±2.6)分,明显优于对照组的(35.9±1.2)分,差异有统计学意义(P<0.05)。结论在恶性胸腹水患者的临床治疗中,采用贝伐单抗联合顺铂腔内灌注方案,可提升临床治疗效果,优化患者的生活质量,提高治疗的安全性,值得临床推广应用。
Objective To observe the clinical effect of bevacizumab plus cisplatin in the treatment of malignant ascites and pleural effusion. Methods Sixty patients with malignant ascites and hydrothorax admitted from March 2013 to September 2014 were selected as study subjects and randomly divided into control group and observation group of 30 cases each. The control group was given cisplatin intracavitary infusion program, observation group received bevacizumab plus cisplatin intracavitary perfusion program. The therapeutic effects, adverse reactions and quality of life scores were compared between the two groups. Measurement data using t test, count data using χ2 test, P <0.05 for the difference was statistically significant. Results The overall remission rate was 80.0% in the observation group and 40.0% in the control group, with significant difference between the two groups (P <0.05). The quality of life score of the observation group after treatment was (46.8 ± 2.6) points, which was significantly better than that of the control group (35.9 ± 1.2) points, the difference was statistically significant (P <0.05). Conclusion In clinical treatment of patients with malignant ascites and hydrothorax, bevacizumab combined with cisplatin intracavitary perfusion program can enhance the clinical treatment effect, optimize the quality of life of patients and improve the safety of treatment, it is worthy of clinical promotion and application.